STAAR Surgical to be Acquired by EssilorLuxottica for $5.7B

TL;DR

STAAR Surgical getting bought by EssilorLuxottica for $5.7 BILLION cash. Deal expected H1 2026.

AI Summary

STAAR Surgical Company announced on October 13, 2025, that it has entered into a definitive agreement to be acquired by an affiliate of EssilorLuxottica for $5.7 billion in cash. The transaction is expected to close in the first half of 2026, subject to customary closing conditions, including regulatory approvals and shareholder approval.

Why It Matters

This acquisition by a major player in the vision care industry could lead to significant changes in the market for refractive surgery products and potentially impact the availability and pricing of STAAR's EVO ICL lenses.

Risk Assessment

Risk Level: medium — The deal is subject to regulatory and shareholder approvals, which introduces uncertainty regarding its completion.

Key Numbers

• $5.7B — Acquisition Price (Total cash consideration for STAAR Surgical Company)

Key Players & Entities

• STAAR Surgical Company (company) — Company being acquired
• EssilorLuxottica (company) — Acquiring company
• $5.7 billion (dollar_amount) — Acquisition price
• October 13, 2025 (date) — Date of agreement
• first half of 2026 (date) — Expected closing period

FAQ

Key Financial Figures

• $185 million — r STAAR, Citi added STAAR's net cash of $185 million as of June 27, 2025 and divided the res
• $16.35 — uity value reference range for STAAR of $16.35 to $23.80, as compared to the closing s
• $23 — reference range for STAAR of $16.35 to $23.80, as compared to the closing share pr
• $17 — R common stock as of August 1, 2025, of $17.76, and the Merger Consideration of $28
• $28.00 — $17.76, and the Merger Consideration of $28.00. The section titled "—Selected Preced
• $17.15 — uity value reference range for STAAR of $17.15 to $30.80, as compared to the closing s
• $30 — reference range for STAAR of $17.15 to $30.80, as compared to the closing share pr
• $29 million — losses carry forwards of approximately $29 million and divided the results by the diluted
• $17.70 — uity value reference range for STAAR of $17.70 to $37.50, as compared to the closing s
• $37 — reference range for STAAR of $17.70 to $37.50, as compared to the closing share pr
• $13.00 — 1, 2025, such price targets ranged from $13.00 to $27.00 for STAAR common stock with a
• $27.00 — uch price targets ranged from $13.00 to $27.00 for STAAR common stock with a median pr
• $19.00 — mon stock with a median price target of $19.00 . Citi also noted that these ranges of
• $11.75 — estimate of STAAR's cost of equity, was $11.75 to $24.40 for STAAR common stock, as co
• $24.40 — f STAAR's cost of equity, was $11.75 to $24.40 for STAAR common stock, as compared to

Filing Documents

• d62063d8k.htm (8-K) — 98KB
• 0001193125-25-238127.txt ( ) — 219KB
• staa-20251013.xsd (EX-101.SCH) — 3KB
• staa-20251013_lab.xml (EX-101.LAB) — 17KB
• staa-20251013_pre.xml (EX-101.PRE) — 11KB
• d62063d8k_htm.xml (XML) — 4KB

Forward-Looking Statements

Forward-Looking Statements The information covered by this communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often contain words such as "anticipate," "believe," "expect," "plan," "estimate," "project," "continue," "will," "should," "may," and similar terms. All statements in this communication that are not statements of historical fact are forward-looking statements. These forward-looking statements are neither promises nor guarantees and involve kn

View Full Filing

View this 8-K filing on SEC EDGAR